Shares of Voyager Therapeutics (VYGR) are down 19% in after-hours trading to $18.50 after the company announced that Sanofi Genzyme (SNY) decided not to exercise its rights to the VY-AADC program for advanced Parkinson’s disease. As a result, Voyager gained
October 30, 2017